Covista Earnings Call Transcripts
Fiscal Year 2026
-
Covista unveiled its 'Purpose at Scale' strategy, targeting 7%-10% revenue CAGR and 10%-14% EPS CAGR through 2029, driven by aggressive campus expansion, digital innovation, and deep employer partnerships. The company is leveraging its scale, AI integration, and disciplined capital allocation to address the U.S. healthcare workforce crisis and deliver double-digit earnings growth.
-
Enrollment and revenue grew strongly across all segments, with Walden and Medical/Vet leading gains. Adjusted EPS guidance was raised to 17%-20% growth, and a new $750M share repurchase authorization was announced.
-
Enrollment and revenue grew strongly year-over-year, with robust performance in Walden and medical/veterinary segments offsetting Chamberlain's marketing execution issues. Full-year guidance is maintained, supported by strong cash flow, margin expansion, and strategic partnerships.
Fiscal Year 2025
-
The meeting confirmed a quorum, elected all ten director nominees, ratified the auditor with 98% approval, and approved executive compensation with over 86% support. Shareholders participated virtually, and results will be filed with the SEC.
-
A leading healthcare education provider is leveraging its national scale and online capabilities to address critical talent shortages, drive operational excellence, and expand through strategic partnerships and disciplined M&A. Favorable regulatory changes and proactive funding solutions support continued growth and value creation.
-
Fiscal 2025 saw double-digit revenue and enrollment growth, margin expansion, and strong free cash flow, driven by strategic investments and partnerships. Guidance for fiscal 2026 projects continued robust growth, with new initiatives in student financing and healthcare employer partnerships supporting long-term momentum.
-
The event highlighted strong enrollment and revenue growth driven by operational excellence, brand positioning, and a focus on nontraditional students in healthcare. The company is leveraging price optimization, marketing improvements, and capacity expansion, while navigating a favorable regulatory environment.
-
Q3 2025 saw 13% revenue growth and 9.8% enrollment increase, with strong gains in Walden and Chamberlain segments. Guidance for FY2025 was raised, and significant capital was returned to shareholders. Regulatory and market conditions remain favorable.
-
Q2 2025 saw 14% revenue growth and 11.6% higher enrollment, with adjusted EPS up 47%. Guidance for fiscal 2025 was raised, expecting 9%-11% revenue growth and over 100 basis points of EBITDA margin expansion. Digital transformation and operational excellence continue to drive results.
-
Q1 FY25 saw revenue rise 13% to $417M and Adjusted EPS jump 39% to $1.29, driven by double-digit enrollment growth across all segments. FY25 guidance was raised for both revenue and EPS, reflecting strong momentum and continued investment in growth and innovation.
Fiscal Year 2024
-
Fiscal 2024 saw 9.2% revenue growth, 19% higher adjusted EPS, and record enrollment gains, with all segments contributing. Fiscal 2025 guidance projects 5–7.5% revenue growth and 12–17% adjusted EPS growth, supported by continued investment and operational leverage.
-
A healthcare-focused education provider is experiencing record enrollment and revenue growth, driven by strategic investments in marketing, technology, and student support. Portfolio synergies, new program launches, and operational improvements are fueling durable growth, with strong financial outlook and proactive risk management.